|
|
|
| The anticoagulant efficacy and safety of Bivalirudin on primary percutaneous coronary intervention in female patients with acute ST-segment elevation myocardial infarction |
| WANG Wenbin CAO Xingmei LI Xin CHENG Guojie TANG Xuehong |
| Department of Cardiology, Beijing Daxing District People′s Hospital, Beijing 102600, China |
|
|
|
Abstract Objective To evaluate anticoagulant efficacy and safety of Bivalirudin on primary percutaneous coronary intervention (PCI) in female patients with acute ST-segment elevation myocardial infarction (STEMI). Methods A total of 182 female patients diagnosed with STEMI undergoing primary PCI in Beijing Daxing District People′s Hospital from January 2016 to January 2018 were selected. According to the using of anticoagulant drugs during primary PCI, they were divided into Bivalirudin group (94 cases) and Heparin with or without Tirofiban group (88 cases). Major adverse cardio cerebral vascular events (MACCE), including cardiac death, non-lethal myocardial infarction, revascularization, stent thrombosis, and ischemic stroke, during hospitalization and within 30 days after primary PCI were evaluated. Bleeding events during hospitalization and within 30 days after primary PCI were evaluated. Results After 30 days′ follow-up, 2 patients occurred MACCE in the Bivalirudin group and 5 patients in the Heparin with or without Tirofiban group, there was no statistically significant difference (P ＞ 0.05). There was no statistically significant difference in bleeding events ratio between the two groups (P ＞ 0.05), but the incidence of hemorrhage during 30 days′ follow-up in the Heparin with or without Tirofiban group was higher than that in the Bivalirudin group, and the difference was statistically significant (P ＜ 0.05). Conclusion To female patients with acute ST- segment elevation myocardial infarction, it can achieve the same anticoagulant effects with better safety by Bivalirudin when the patients are treated with PCI.
|
|
|
|
|
|
[1] Dalby M，Bouzamondo A，Lechat P，et al. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction-A meta-analysis [J]. Circulation，2003，108（15）：1809-1814.
[2] Brown MD，Byyny R，Diercks DB，et al. “Clinical Policy：Emergency Department Management of Patients Needing Reperfusion Therapy for Acute ST-Segment Elevation Myocardial Infarction”[J]. Ann Emerg Med，2017，70（5）：724-739.
[3] Warkentin TE，Greinacher A，Koster A. Bivalirudin [J]. Thromb Haemost，2008，99（5）：830-839.
[4] Sciulli TM，Mauro VF. Pharmacology and clinical use of bivalirudin [J]. Ann Pharmacother，2002，36（6）：1028-1041.
[5] Bates SM，Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis：potential differences between bivalirudin and hirudin [J]. Am J Cardiol，1998，82（8B）：12P-18P.
[6] Barria Perez AE，Rao SV，Jolly SJ，et al. Meta-Analysis of effects of bivalirudin versus heparin on myocardial ischemic and bleeding outcomes after percutaneous coronary intervention [J]. Am J Cardiol，2016，117（8）：1256-1266.
[7] Verheugt FW. Anticoagulant management in the cardiovascular setting [J]. Fundam Clin Pharmacol，2012，26（1）：11-5.
[8] Hess CN，Mccoy LA，Duggirala HJ，et al. Sex-Based Differences in Outcomes After Percutaneous Coronary Intervention for Acute Myocardial Infarction：A Report From TRANSLATE-ACS [J]. J Am Heart Assoc，2014，3（1）：e000 523.
[9] Stone GW，Witzenbichler B，Guagliumi G，et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction [J]. N Engl J Med，2008，358：2218-2230.
[10] Giustino G，Mehran R，Bansilal S，et al. Safety and efficacy of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention：from the REPLACE-2，ACUITY and HORIZONS-AMI Trials [J]. Am J Cardiol，2016，118（1）：6-16.
[11] Dangas GD，Schoos MM，Steg PG，et al. Early stent thrombosis and mortality after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction：a patient-level analysis of 2 randomized trials [J]. Circ Cardiovasc Interv，2016，9（5）：276-289.
[12] Ng VG，Baumbach A，Grinfeld L，et al. Impact of bleeding and Bivalirudin therapy on mortality risk in women undergoing percutaneous coronary intervention（from the REPLACE-2，bleed acuity，and horizons-AMI trials） [J]. Am J Cardiol，2016，117（2）：186-191.
[13] Yu J，Mehran R，Clayton T，et al. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk：a patient-level pooled analysis from three randomized trials [J]. Catheter Cardiovasc Interv，2016，87（3）：391-400.
[14] Liang Z，Li Y，Wang J，et al. The safety and effectiveness of Bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty：a subgroup analysis of the BRIGHT trial [J]. Catheter Cardiovasc Interv，2016，3（87）：608-615.
[15] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.2015急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志，2015，43（5）：380-393.
[16] Mehran R，Rao SV，Bhatt DL，et al. Standardized bleeding definitions for cardiovascular clinical trials：a consensus report from the Bleeding Academic Research Consortium [J]. Circulation，2011，123（23）：2736-2747.
[17] 王小东，刘俊波.急性冠脉综合征新型抗凝药物研究进展[J].国际心血管病杂志，2015，42（1）：6-9.
[18] 王现涛，苏强.比伐卢定在心血管介入治疗中应用的研究进展[J].中华老年心脑血管病杂志，2014，16（6）：655-657.
[19] 张慧，郑晓群.比伐卢定在急性冠脉综合征中的应用进展[J].心血管病学进展，2015，36（3）：352-355.
[20] Valgimigli M，Frigoli E，Leonardi S，et al. Bivalirudin or unfractionated heparin in acute coronary syndromes [J]. N Engl J Med，2015，373（11）：997-1009.
[21] Han Y，Guo J，Zheng Y，et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction：the BRIGHT randomized clinical trial [J]. JAMA，2015，313（13）：1336-1346.
[22] Bertrand OF，Jolly SS，Ｒao SV，et al. Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention [J]. Am J Cardiol，2012，110（4）：599-606.
[23] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南[J].中华心血管病学杂志，2016，44（5）：382-400. |
|
|
|
